Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Patient-Controlled Analgesia for Acute Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Total Injury Severity Score greater than 9~* Functioning intravenous catheter present per standard of care~* Patient planned to receive PCA for acute pain per standard of care~* Patient ability to effectively use a PCA device as assessed by the primary attending trauma service~* Negative pregnancy test for women of childbearing age~Exclusion Criteria:~* Body mass index greater than 35~* History of active psychiatric disease~* Acute or chronic liver or renal failure~* History of heart failure or coronary artery disease~* Patients with documented chronic pain syndrome who use opioids as maintenance medication in outpatient therapy~* Patients who abuse alcohol and are at high risk for alcohol withdrawal~* Intubated patients~* Glasgow Coma Scale score less than 13, or motor subscore less than 6~* Documented allergy to ketamine, hydromorphone, or lorazepam~* Pregnancy~* Incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Ketamine 90mg/30 mL PCA (3 mg/mL)
- Hydromorphone (Type: ACTIVE_COMPARATOR): Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).